Investigational urate elevation does not appear to raise hypertension risk

November 9, 2018, Massachusetts General Hospital

A study from a group of Massachusetts General Hospital (MGH) investigators may reduce the concern that elevating levels of urate, an approach being investigated to treat several neurodegenerative disorders, could increase the risk of hypertension. The study authors—several of whom previously conducted a phase 2 trial finding that the drug inosine safely elevated urate levels in patients with early Parkinson disease—are reporting their most recent findings in EBioMedicine, an open-access journal published by The Lancet.

"Our study does not support a hypertensive effect from urate elevation," says Xiqun Chen, MD, Ph.D., of the MGH Department of Neurology, lead author of the EBioMedicine report. "It also highlights the need for a more careful evaluation of urate-lowering treatments being investigated to treat hypertension."

Animal studies have suggested that the antioxidant urate could have neuroprotective effects, and observations in human —associations between naturally higher urate levels and reduced risk of developing Parkinson disease or slower disease progression—led to initiation of the two-year, phase 2 SURE-PD clinical trial, led by MGH neurologist Michael Schwarzschild, MD, Ph.D., senior author of the current study. The encouraging results of that trial, which enrolled 75 newly diagnosed Parkinson disease patients with relatively low urate levels, led to the initiation of the larger SURE-PD Phase 3 trial, which is currently underway.

But because significant evidence has suggested that higher urate is associated with hypertension, the team took a closer look at any potential effects on blood pressure among participants in the phase 2 SURE-PD trial. Among all three groups of participants—those receiving doses producing mild or moderate urate elevation or those receiving a placebo—there were no significant differences in blood pressure readings taken before, during or after the 18- to 24-month study period.

Those findings were further supported by experiments in mouse models genetically engineered to have either reduced urate or mild or moderate urate elevation. Those studies found no association of altered urate levels with significant differences in blood pressures between any of the genetically engineered mice and genetically unaltered control animals. In addition, the use of blood-pressure-manipulating agents had similar effects both on animals with elevated urate and on the controls, adding additional support to a lack of connection between and .

"Together with the original report on the SURE-PD trial, this study provides strong evidence that long-term administration of oral inosine can be generally safe in patients with early Parkinson disease." says Chen, who is an assistant professor of Neurology at Harvard Medical School (HMS). "Although those SURE-PD participants were otherwise healthy with no obvious cardiovascular or renal , these findings may not be generalized to all patients. More studies are needed to definitively determine the role of urate in hypertension—including the potential of the urate-lowering drugs currently being investigated. Meanwhile, we are taking advantage of the current phase 3 inosine trial to monitor any possible risks of urate elevation in a larger group of patients."

Explore further: Drug combination benefits patients with tophaceous gout

More information: Xiqun Chen et al, Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease, EBioMedicine (2018). DOI: 10.1016/j.ebiom.2018.10.039

Related Stories

Drug combination benefits patients with tophaceous gout

June 9, 2017
The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout. Over 12 months, significantly more patients ...

Research shows diet has little influence on precursor to gout

October 11, 2018
Dietary factors have a far smaller influence on urate levels (a precursor to gout) than previously envisaged, new University of Otago research reveals.

High levels of urate in blood associated with lower risk of Parkinson's disease

January 13, 2016
Men who have high levels of urate, also known as uric acid, in their blood may be less likely to develop Parkinson's disease, according to a study published in the Jan. 13, 2016, online issue of Neurology, the medical journal ...

Inosine treatment safely elevates urate levels in Parkinson's disease patients

December 23, 2013
A clinical trial assessing the potential of the nutritional supplement inosine to treat Parkinson disease has found that the studied dosages successfully raised participants' levels of the antioxidant urate without producing ...

Genetic manipulation of urate alters neurodegeneration in mouse model of Parkinson's disease

December 17, 2012
A study by Massachusetts General Hospital researchers adds further support to the possibility that increasing levels of the antioxidant urate may protect against Parkinson's disease. In their report published in PNAS Early ...

Febuxostat prevents gout flares in recent clinical trial

October 4, 2017
As reported in the journal Arthritis & Rheumatology, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout. Febuxostat treatment also reduced synovitis—or inflammation ...

Recommended for you

Proteins cooperate to break up energy structures in oxygen starved heart cells

November 19, 2018
During a heart attack, the supply of oxygen to heart cells is decreased. This reduced oxygen level, called hypoxia, causes the cell's powerhouses, the mitochondria, to fragment, impairing cell function and leading to heart ...

Researchers a step closer to understanding how deadly bird flu virus takes hold in humans

November 19, 2018
New research has taken a step towards understanding how highly pathogenic influenza viruses such as deadly bird flu infect humans.

Bullying and violence at work increases the risk of cardiovascular disease

November 19, 2018
People who are bullied at work or experience violence at work are at higher risk of heart and brain blood vessel problems, including heart attacks and stroke, according to the largest prospective study to investigate the ...

Genetic analysis links obesity with diabetes, coronary artery disease

November 16, 2018
A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease. The paper was published ...

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.